Objective To observe the expression levels of Mig in the patients with chronic hepatitis B .Methods The study pop‐ulation consisted of 88 chronic hepatitis B patients and 53 healthy controls .The ELISA ,RT‐PCR and Western‐blotting were used for analysing the expression levels of Mig in serum ,peripheral blood mononuclear cells and liver tissue of the patients with chronic hepatitis B ,while the immunohistochemistry was applied for analysing the distribution of Mig in liver tissue .Results The expres‐sion of Mig in serum ,peripheral blood mononuclear cells and liver tissue of the chronic hepatitis B patients with HBeAg negative were (247 .03 ± 63 .14)pg/mL ,(0 .95 ± 0 .21) ,(0 .79 ± 0 .23) ,and that in the chronic hepatitis B patients with HBeAg positive were (243 .05 ± 53 .00)pg/mL ,(0 .98 ± 0 .35) ,(0 .74 ± 0 .18) ,which were both significantly higher than those in healthy controls ,the difference was statistically significant(P<0 .05) .Conclusion Increased levels of Mig in the patients with chronic hepatitis B may be related to immune state of patients .

ObjectiveTo investigate the association between cuplike nuclei morphology and FLT3-ITD mutation, so as to provide evidence for the minor classification of AML. MethodsThe articles on the association of cuplike nuclei morphology and FLT3-ITD mutation were retrieved by searching international and national databases from 1999 to 2011. The relationship was assessed by meta analysis with Statal 1 software.The OR value and confidence interval(CI)were calculated, and the publication bias was assessed by Begg test and Egger test.ResultsThere was significant difference between cuplike nuclei morphology appearance and FLT3-ITD mutation (OR =2.59,95 ％ CI 1.55-4.33,P =0.00).Results from both Begg' s test and Egger’ s test did not show significant difference indicating that there was no publication bias existed.ConclusionThe uncommon morphologic variant of AML with cuplike nuclei is highly associated with FLT3-ITD mutation, and the presence of cuplike nuclei in AML represents a distinctive morphologic finding that can be used to prioritize the molecular workup of patients with AML.